Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATOS Atossa Therapeutics	$0.78 +3.2%	$0.76	$0.55 ▼ $1.66	$101.33M	1.01	780,746 shs	691,070 shs
BDTX Black Diamond Therapeutics	$2.23 -0.9%	$1.67	$1.20 ▼ $6.75	$126.80M	2.63	1.51 million shs	945,891 shs
KZR Kezar Life Sciences	$4.17	$4.27	$3.62 ▼ $9.18	$30.47M	0.61	56,806 shs	5,063 shs
NMRA Neumora Therapeutics	$0.71 -1.3%	$0.74	$0.61 ▼ $17.19	$116.25M	2.96	1.51 million shs	438,155 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATOS Atossa Therapeutics	+3.16%	-5.68%	-12.63%	+2.46%	-40.57%
BDTX Black Diamond Therapeutics	-0.89%	+10.95%	+31.18%	+10.95%	-53.05%
KZR Kezar Life Sciences	0.00%	+6.11%	-4.79%	-26.97%	-39.45%
NMRA Neumora Therapeutics	-1.31%	+4.35%	-9.04%	-54.53%	-92.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATOS Atossa Therapeutics	1.4523 of 5 stars	3.5	0.0	0.0	2.6	1.7	0.0
BDTX Black Diamond Therapeutics	3.5688 of 5 stars	3.5	4.0	0.0	3.3	2.5	1.3
KZR Kezar Life Sciences	4.5032 of 5 stars	3.2	5.0	4.6	2.9	2.5	0.6
NMRA Neumora Therapeutics	2.8398 of 5 stars	4.1	0.0	0.0	2.6	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATOS Atossa Therapeutics	3.00	Buy	$7.13	808.22% Upside
BDTX Black Diamond Therapeutics	3.00	Buy	$14.60	554.71% Upside
KZR Kezar Life Sciences	2.33	Hold	$39.50	847.24% Upside
NMRA Neumora Therapeutics	2.22	Hold	$9.29	1,209.14% Upside

Current Analyst Ratings Breakdown

Latest KZR, BDTX, NMRA, and ATOS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/13/2025	NMRA Neumora Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/21/2025	ATOS Atossa Therapeutics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $7.25
4/10/2025	NMRA Neumora Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/2/2025	NMRA Neumora Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Underperform	$7.00 ➝ $1.00
3/26/2025	ATOS Atossa Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
3/19/2025	BDTX Black Diamond Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$11.00
3/18/2025	BDTX Black Diamond Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $12.00
3/12/2025	ATOS Atossa Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
3/10/2025	NMRA Neumora Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
3/7/2025	BDTX Black Diamond Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
3/7/2025	BDTX Black Diamond Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$16.00 ➝ $11.00

(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATOS Atossa Therapeutics	N/A	N/A	N/A	N/A	$0.73 per share	N/A
BDTX Black Diamond Therapeutics	$70M	1.81	N/A	N/A	$2.26 per share	0.99
KZR Kezar Life Sciences	$7M	4.35	N/A	N/A	$25.80 per share	0.16
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$3.07 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATOS Atossa Therapeutics	-$30.09M	-$0.21	N/A	N/A	N/A	N/A	-35.74%	-33.51%	8/11/2025 (Estimated)
BDTX Black Diamond Therapeutics	-$82.44M	$0.06	N/A	N/A	N/A	N/A	-68.08%	-49.65%	8/5/2025 (Estimated)
KZR Kezar Life Sciences	-$101.87M	-$10.82	N/A	N/A	N/A	N/A	-54.95%	-46.11%	8/12/2025 (Estimated)
NMRA Neumora Therapeutics	-$235.93M	-$1.61	N/A	N/A	N/A	N/A	-73.63%	-68.97%	8/5/2025 (Estimated)

Latest KZR, BDTX, NMRA, and ATOS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ATOS Atossa Therapeutics	-$0.06	-$0.05	+$0.01	-$0.05	N/A	N/A
5/13/2025	Q1 2025	KZR Kezar Life Sciences	-$2.56	-$2.27	+$0.29	-$2.27	N/A	N/A
5/12/2025	Q1 2025	NMRA Neumora Therapeutics	-$0.40	-$0.42	-$0.02	-$0.42	N/A	N/A
3/25/2025	Q4 2024	ATOS Atossa Therapeutics	-$0.0633	-$0.05	+$0.0133	-$0.05	N/A	N/A
3/25/2025	Q4 2024 & Study Result	KZR Kezar Life Sciences	-$2.71	-$2.77	-$0.06	-$2.77	N/A	N/A
3/6/2025	Q4 2024	BDTX Black Diamond Therapeutics	-$0.31	-$0.28	+$0.03	-$0.28	N/A	N/A
3/6/2025	Q4 2024	NMRA Neumora Therapeutics	-$0.46	-$0.37	+$0.09	-$0.37	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATOS Atossa Therapeutics	N/A	N/A	N/A	N/A	N/A
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	N/A
KZR Kezar Life Sciences	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATOS Atossa Therapeutics	N/A	13.30	13.30
BDTX Black Diamond Therapeutics	N/A	5.55	5.55
KZR Kezar Life Sciences	0.05	7.65	7.65
NMRA Neumora Therapeutics	N/A	10.98	10.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATOS Atossa Therapeutics	12.74%
BDTX Black Diamond Therapeutics	95.47%
KZR Kezar Life Sciences	67.90%
NMRA Neumora Therapeutics	47.65%

Insider Ownership

Company	Insider Ownership
ATOS Atossa Therapeutics	8.70%
BDTX Black Diamond Therapeutics	8.87%
KZR Kezar Life Sciences	10.40%
NMRA Neumora Therapeutics	26.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATOS Atossa Therapeutics	8	129.17 million	116.24 million	Optionable
BDTX Black Diamond Therapeutics	90	56.86 million	51.57 million	Optionable
KZR Kezar Life Sciences	60	7.31 million	6.62 million	Not Optionable
NMRA Neumora Therapeutics	108	161.75 million	118.91 million	Optionable

KZR, BDTX, NMRA, and ATOS Headlines

Recent News About These Companies

Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm

May 27, 2025 | globenewswire.com

Neumora Therapeutics’s SWOT analysis: navigating challenges in neuropsychiatric drug development

May 24, 2025 | uk.investing.com

Softbank Group CORP. Has $69.34 Million Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

May 18, 2025 | marketbeat.com

HC Wainwright Has Pessimistic Outlook of NMRA Q2 Earnings

May 17, 2025 | marketbeat.com

Q2 EPS Forecast for Neumora Therapeutics Raised by Analyst

May 17, 2025 | marketbeat.com

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Sold by Price T Rowe Associates Inc. MD

May 17, 2025 | marketbeat.com

Needham & Company LLC Reiterates "Buy" Rating for Neumora Therapeutics (NASDAQ:NMRA)

May 15, 2025 | marketbeat.com

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Stock Holdings Lessened by Orbimed Advisors LLC

May 15, 2025 | marketbeat.com

Neumora Therapeutics (NASDAQ:NMRA) Posts Earnings Results, Misses Expectations By $0.02 EPS

May 14, 2025 | marketbeat.com

Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm

May 14, 2025 | prnewswire.com

Neumora Therapeutics, Inc.: Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025 | finanznachrichten.de

Neumora Therapeutics Inc (NMRA) Q1 2025 Earnings Call Highlights: Advancing Brain Disease ...

May 13, 2025 | finance.yahoo.com

Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call Transcript

May 12, 2025 | seekingalpha.com

Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025 | globenewswire.com

Will Neumora Therapeutics (NASDAQ:NMRA) Spend Its Cash Wisely?

May 11, 2025 | finance.yahoo.com

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of "Hold" by Analysts

May 9, 2025 | marketbeat.com

Schonfeld Strategic Advisors LLC Increases Stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

May 5, 2025 | marketbeat.com

Neumora Therapeutics (NMRA) Expected to Announce Quarterly Earnings on Tuesday

May 1, 2025 | marketbeat.com

Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

April 28, 2025 | globenewswire.com

Why Neumora Therapeutics, Inc.’s (NMRA) Stock Is Up 10.34%

April 23, 2025 | aaii.com

Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm

April 16, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZR, BDTX, NMRA, and ATOS Company Descriptions

Atossa Therapeutics NASDAQ:ATOS

$0.78 +0.02 (+3.16%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$0.78 -0.01 (-1.21%)

As of 05/30/2025 07:01 PM Eastern

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Black Diamond Therapeutics NASDAQ:BDTX

$2.23 -0.02 (-0.89%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$2.24 +0.01 (+0.45%)

As of 05/30/2025 07:56 PM Eastern

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Kezar Life Sciences NASDAQ:KZR

$4.17 0.00 (0.00%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$4.18 +0.00 (+0.12%)

As of 05/30/2025 04:04 PM Eastern

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Neumora Therapeutics NASDAQ:NMRA

$0.71 -0.01 (-1.31%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$0.71 0.00 (-0.18%)

As of 05/30/2025 07:48 PM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time